Evidence map›Paper›PMID 41820555›Full record

ArticleNature microbiology2026

Epitope-focused discovery of SARS-CoV-2 antibodies that potently neutralize Omicron variants.

Seth J Zost, Naveenchandra Suryadevara, Lauren E Williamson, Suzanne M Scheaffer, Elad Binshtein, Cameron D Buchman, Nicole V Johnson, Nicholas J Catanzaro, Silvia Ravera, Nathaniel S Chapman and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Seth J Zost *The Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-6712-5076
Naveenchandra Suryadevara *The Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-2571-1290
Lauren E Williamson *The Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-2725-5826
Suzanne M ScheafferDepartment of Medicine, Washington University School of Medicine, StLouis, MO, USA.
Elad BinshteinThe Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA.
Cameron D BuchmanThe Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-2550-649X
Nicole V JohnsonDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Nicholas J CatanzaroDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-0210-8440
Silvia RaveraThe Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA.
Nathaniel S ChapmanDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Luke MyersThe Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-1132-2550
Ajit R RamamohanDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Laura S HandalThe Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-8658-4411
Doan C NguyenDepartment of Medicine, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-5389-6731
Andrew TrivetteThe Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA.
James R MartinezThe Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0009-0001-8260-6916
Eduardo VillalobosThe Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-5197-6367
Stacey A RutherfordThe Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA.
F Eun-Hyung LeeDepartment of Medicine, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-6133-5942
Alexandra SchäferDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-4760-4923
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-6827-8701
Jason S McLellanDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0003-3991-542X
Michael S DiamondDepartment of Medicine, Washington University School of Medicine, StLouis, MO, USA.ORCID http://orcid.org/0000-0002-8791-3165
Robert H CarnahanThe Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-5230-1532
James E CroweThe Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA. james.crowe@vumc.org.ORCID http://orcid.org/0000-0002-0049-1079

Funding

ODCDC CDC HHS S10 OD030292United States Department of Defense | Defense Advanced Research Projects Agency (DARPA) HR0011-18-2-0001U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI157155
6 · The paper itself

Abstract

The emergence of SARS-CoV-2 Omicron variants has led to viral escape from many clinically approved monoclonal antibodies (mAbs) due to rapid evolution of the receptor-binding domain (RBD). Co-circulation of SARS-CoV-2 variants with unique sets of antigenic substitutions has further complicated therapeutic mAb discovery. New approaches are needed to rapidly discover and characterize mAbs with preferred specificity and functional characteristics. Here we describe and perform epitope-focused mAb discovery using glycan-masked antigens. We isolated and expressed a panel of 303 mAbs, some of which potently neutralize divergent Omicron subvariants by targeting the class 3 antigenic site on SARS-CoV-2 RBD. Epitope mapping of these antibodies revealed a spectrum of cross-reactivity and differential recognition of the class 3 site, validating the utility of this enrichment approach for targeted mAb discovery. Together, this work rationally designs glycan-masked engineered RBDs and uses them to isolate mAbs that potently neutralize antigenically divergent SARS-CoV-2 variants.

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEpitopesSARS-CoV-2AnimalsCOVID-19Cross ReactionsEpitope MappingHumansPolysaccharidesSpike Glycoprotein, CoronavirusAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEpitopesPolysaccharidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID41820555
PMCPMC13056569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.